A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
General Information We are a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. We are driven by our mission: Safeguarding Global Health®. We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world. In 2025, our customers included over 40 of the top 50 medical device companies and nine of the top ten global pharmaceutical companies (based on revenue). Our services are an essential aspect of our customers’ manufacturing processes and supply chains, helping to ensure sterilized medical products reach healthcare practitioners and patients. Most of our services are necessary for our customers to satisfy applicable government requirements.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.2B | 1.2B | 1.1B | 1.0B | 1.0B | 931M |
| Net Income | 78M | 78M | 44M | 51M | -234M | 115M |
| EPS | $0.27 | $0.27 | $0.16 | $0.18 | $-0.83 | $0.41 |
| Free Cash Flow | 149M | 149M | 45M | -363M | 96M | 179M |
| ROIC | 3.3% | 3.8% | 7.5% | 7.7% | 12.0% | 7.7% |
| Gross Margin | 55.5% | 55.5% | 54.7% | 55.0% | 55.5% | 55.7% |
| Debt/Equity | 3.59 | 3.59 | 5.56 | 5.08 | 5.63 | 3.05 |
| Dividends/Share | $0.00 | - | - | - | - | $0.00 |
| Operating Income | 154M | 154M | 298M | 277M | 248M | 257M |
| Operating Margin | 13.2% | 13.2% | 27.0% | 26.4% | 24.7% | 27.6% |
| ROE | 12.9% | 15.4% | 10.4% | 12.9% | -49.9% | 22.2% |
| Shares Outstanding | 289M | 289M | 277M | 284M | 281M | 281M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 778M | 818M | 931M | 1.0B | 1.0B | 1.1B | 1.2B | 1.2B |
| Gross Margin | 50.8% | 54.2% | 55.7% | 55.5% | 55.0% | 54.7% | 55.5% | 55.5% |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | 147M | 179M | 198M | 246M | 237M | 243M | 253M | 253M |
| EBIT | 184M | 206M | 257M | 248M | 277M | 298M | 154M | 154M |
| Op. Margin | 23.6% | 25.2% | 27.6% | 24.7% | 26.4% | 27.0% | 13.2% | 13.2% |
| Net Income | -21M | -39M | 115M | -234M | 51M | 44M | 78M | 78M |
| Net Margin | -2.7% | -4.7% | 12.4% | -23.3% | 4.9% | 4.0% | 6.7% | 6.7% |
| Non-Recurring | 5.8M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | 20.3% | 10.1% | 7.7% | 12.0% | 7.7% | 7.5% | 3.8% | 3.3% |
| ROE | 7.0% | 40.9% | 22.2% | -49.9% | 12.9% | 10.4% | 15.4% | 12.9% |
| ROA | -26.0% | -2.7% | 4.2% | -7.9% | 1.6% | 1.4% | 2.5% | 2.4% |
| Cash Flow | ||||||||
| Op. Cash Flow | 149M | 121M | 282M | 278M | -148M | 224M | 287M | 287M |
| Free Cash Flow | 92M | 67M | 179M | 96M | -363M | 45M | 149M | 149M |
| Owner Earnings | 75M | 46M | 203M | 192M | -257M | 103M | 161M | 161M |
| CapEx | 57M | 54M | 102M | 182M | 215M | 179M | 138M | 138M |
| Maint. CapEx | 67M | 63M | 64M | 64M | 77M | 84M | 95M | 95M |
| Growth CapEx | 0 | 0 | 38M | 118M | 138M | 95M | 43M | 43M |
| D&A | 67M | 63M | 64M | 64M | 77M | 84M | 95M | 95M |
| CapEx/OCF | N/A | 44.4% | 36.3% | 65.6% | N/A | 79.9% | 48.1% | 48.1% |
| Capital Allocation | ||||||||
| Dividends Paid | 691M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 34M | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | 0.5% | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 6.9M | 11M | 14M | 21M | 32M | 37M | 31M | 31M |
| Debt Repayment | 2.6B | 1.2B | 100M | 0 | 2.5M | 2.3B | 86M | 86M |
| Balance Sheet | ||||||||
| Net Debt | 2.5B | 1.8B | 1.7B | 1.6B | 2.0B | 2.0B | 1.8B | 1.8B |
| Cash & Equiv. | 63M | 102M | 107M | 395M | 296M | 277M | 345M | 345M |
| Long-Term Debt | 2.6B | 1.8B | 1.7B | 1.7B | 2.2B | 2.2B | 2.1B | 2.1B |
| Debt/Equity | -3.99 | 4.14 | 3.05 | 5.63 | 5.08 | 5.56 | 3.59 | 3.59 |
| Interest Coverage | 1.2 | 104.7 | 102.4 | 71.9 | 63.0 | 49.1 | 25.2 | 25.2 |
| Equity | -641M | 452M | 586M | 350M | 444M | 405M | 606M | 606M |
| Total Assets | 80M | 2.8B | 2.8B | 3.1B | 3.1B | 3.1B | 3.3B | 3.3B |
| Total Liabilities | 721M | 2.3B | 2.2B | 2.8B | 2.7B | 2.7B | 2.7B | 2.7B |
| Intangibles | N/A | 643M | 599M | 491M | 416M | 318M | 288M | 288M |
| Retained Earnings | N/A | -589M | -472M | -706M | -654M | -610M | -532M | -532M |
| Working Capital | N/A | 174M | 185M | -147M | 327M | 335M | 364M | 364M |
| Current Assets | N/A | 315M | 346M | 645M | 557M | 526M | 613M | 613M |
| Current Liabilities | 724K | 141M | 161M | 792M | 231M | 191M | 250M | 250M |
| Per Share Data | ||||||||
| EPS | -0.09 | -0.16 | 0.41 | -0.83 | 0.18 | 0.16 | 0.27 | 0.27 |
| Owner EPS | 0.33 | 0.19 | 0.72 | 0.68 | -0.90 | 0.37 | 0.56 | 0.56 |
| Book Value | -2.77 | 1.87 | 2.08 | 1.24 | 1.56 | 1.46 | 2.10 | 2.10 |
| Cash Flow/Share | 0.64 | 0.50 | 1.00 | 0.99 | -0.52 | 0.81 | 0.99 | 0.60 |
| Dividends/Share | 2.98 | 0.00 | 0.00 | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 231.7M | 241.4M | 281.4M | 281.4M | 283.8M | 277.1M | 288.7M | 288.7M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | 57.0 | N/A | 95.3 | 84.2 | 65.6 | 59.0 |
| P/FCF | N/A | 99.2 | 36.6 | 22.9 | N/A | 82.8 | 34.3 | 30.8 |
| EV/EBIT | N/A | 40.2 | 31.9 | 14.3 | 23.6 | N/A | 769.4 | 41.9 |
| Price/Book | N/A | 14.7 | 11.4 | 6.3 | 11.0 | 9.2 | 8.4 | 7.6 |
| Price/Sales | N/A | 7.9 | 7.6 | 4.7 | 4.3 | 3.5 | 3.4 | 4.0 |
| FCF Yield | N/A | 1.0% | 2.7% | 4.4% | -7.4% | 1.2% | 2.9% | 3.2% |
| Market Cap | N/A | 6.7B | 6.7B | 2.2B | 4.9B | 3.7B | 5.1B | 4.6B |
| Avg. Price | N/A | 26.75 | 24.84 | 16.70 | 15.81 | 13.86 | 13.77 | 15.93 |
| Year-End Price | N/A | 27.58 | 23.36 | 7.79 | 17.16 | 13.48 | 17.70 | 15.93 |
Sotera Health Co passes 2 of 9 quality checks, indicating weak fundamentals.
Sotera Health Co trades at 59.0x trailing earnings, compared to its 15-year median P/E of 74.9x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 30.4x vs a median of 36.6x. The company's 5-year average ROIC is 7.8% with a gross margin of 55.3%. At current prices, the estimated annualized return to fair value is -1.7%.
Sotera Health Co (SHC) has a current P/E ratio of 59.0, compared to its historical median P/E of 74.9. The stock is currently considered Cheap based on its historical valuation range.
Sotera Health Co (SHC) has a 5-year average return on invested capital (ROIC) of 7.8%. This is below average and may indicate limited pricing power.
Sotera Health Co (SHC) has a market capitalization of $4.6B. It is classified as a mid-cap stock.
Sotera Health Co (SHC) does not currently pay a regular dividend.
Based on historical P/E analysis, Sotera Health Co (SHC) appears cheap. The current P/E of 59.0 is 21% below its historical median of 74.9. The estimated fair value CAGR (P/E method) is 11.7%.
Sotera Health Co (SHC) operates in the Services-Misc Health & Allied Services, Nec industry, within the Healthcare sector.
Sotera Health Co (SHC) reported annual revenue of $1.2 billion in its most recent fiscal year, based on SEC EDGAR filings.
Sotera Health Co (SHC) has a net profit margin of 6.7%. This is a modest margin.
Sotera Health Co (SHC) generated $149 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Sotera Health Co (SHC) has a debt-to-equity ratio of 3.59. This indicates higher leverage, which may increase financial risk.
Sotera Health Co (SHC) reported earnings per share (EPS) of $0.27 in its most recent fiscal year.
Sotera Health Co (SHC) has a return on equity (ROE) of 15.4%. This indicates the company generates strong returns for shareholders.
Sotera Health Co (SHC) has a 5-year average gross margin of 55.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 7 years of financial data for Sotera Health Co (SHC), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Sotera Health Co (SHC) has a book value per share of $2.10, based on its most recent annual SEC filing.
No recent press releases.